AGE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AGE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
AgeX Therapeutics's EBITDA per Share for the three months ended in Dec. 2023 was $-3.20.
During the past 3 years, the average EBITDA Per Share Growth Rate was -238.10% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -109.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of AgeX Therapeutics was 14.10% per year. The lowest was -238.10% per year. And the median was -88.65% per year.
For the Biotechnology subindustry, AgeX Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, AgeX Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where AgeX Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
AgeX Therapeutics (AMEX:AGE) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Thank you for viewing the detailed overview of AgeX Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Jean-christophe Renondin | director | 505 PARK AVENUE 14TH FLOOR, NEW YORK NY 10022 |
Juvenescence Us Corp. | director, 10 percent owner | 303A COLLEGE ROAD EAST, PRINCETON NJ 08540 |
Joanne M. Hackett | director | C/O AGEX THERAPEUTICS, INC.,, 1101 MARINA VILLAGE PARKWAY, SUITE 201, ALAMEDA CA 94708 |
Park Andrea Eun Jae | officer: Chief Financial Officer | C/O AGEX THERAPEUTICS, INC., 965 ATLANTIC AVE., SUITE 101, ALAMEDA CA 94501 |
Michael H May | director | 965 ATLANTIC AVENUE, SUITE 101, ALAMEDA CA 94501 |
Michael D West | director, officer: Chief Executive Officer | AGEX THERAPEUTICS, INC., 1101 MARINA VILLAGE PARKWAY, SUITE 201, ALAMEDA CA 94501 |
Michael H. Mulroy | director | 1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92807 |
Russell Skibsted | officer: Chief Financial Officer | 15 TRANQUILITY PLACE, LADERA RANCH CA 92694 |
Judith Segall | officer: Corporate Secretary | 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501 |
Hal Sternberg | officer: Vice President-Research | 935 PARDEE STREET, BERKELEY CA 94710 |
Annalisa Jenkins | director | C/O ARDELYX, INC., 34715 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555 |
John F Mauldin | director | 3204 BEVERLY DRIVE, DALLAS TX 75205 |
Gregory Bailey | director | 4 A CHESHAM STREET, LONDON X0 SW1X8DT |
Juvenescence Ltd | 10 percent owner | 1ST FLOOR, VIKING HOUSE, ST PAULS SQUARE, RAMSEY Y8 IM8 1GB |
Nafees Naseer Malik | officer: Chief Operating Officer | C/O AGEX THERAPEUTICS, INC., 1010 ATLANTIC AVE, STE 102, ALAMEDA CA 94501 |
From GuruFocus
By Marketwired • 09-15-2023
By PRNewswire • 10-10-2023
By PRNewswire • 09-26-2023
By PRNewswire • 10-10-2023
By PRNewswire • 08-30-2023
By Marketwired • 09-18-2023
By PRNewswire • 09-06-2023
By Marketwired • 08-30-2023
By PRNewswire • 10-24-2023
By PRNewswire • 10-24-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.